Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 4% / Sodium chloride 0.18% infusion 1litre Viaflo bags

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Glucose anhydrous; Potassium chloride; Sodium chloride

Pieejams no:

potassium 40mmol/1litre) / Glucose 4% / Sodium chloride 0.18% infusion 1litre Viaflo bags (Baxter Healthcare Ltd

ATĶ kods:

B05BB02

SNN (starptautisko nepatentēto nosaukumu):

Glucose anhydrous; Potassium chloride; Sodium chloride

Deva:

40mg/1ml ; 3mg/1ml ; 1.8mg/1ml

Zāļu forma:

Infusion

Ievadīšanas:

Intravenous

Klase:

No Controlled Drug Status

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 09020201; GTIN: 5413760216119 55413760216114

Produkta apraksts

OBJECT 1
POTASSIUM CHLORIDE 0.3%, SODIUM CHLORIDE 0.18
% AND GLUCOSE 4% SOLUTION FOR INFUSION BP
Summary of Product Characteristics Updated 01-Apr-2015 | Baxter
Healthcare Ltd
1. Name of the medicinal product
Potassium Chloride 0.3%, Sodium Chloride 0.18 % and Glucose 4%
Solution for Infusion BP.
2. Qualitative and quantitative composition
Potassium Chloride
Sodium Chloride:
Glucose monohydrate:
3.0 g/l
1.8 g/l
44.0 g/l
mmol/l
mEq/l
K
+
40
40
Na
+
31
31
Cl
-
71
71
For the full list of excipients: see Section 6.1.
3. Pharmaceutical form
Solution for infusion.
Clear solution, free from visible particles.
4. Clinical particulars
4.1 Therapeutic indications
Prevention and treatment of potassium, sodium and chloride depletion
due to a loss of gastrointestinal
fluid (vomiting, diarrhoea, surgical drainage, gastric suction, small
intestinal bypass procedure, or small
bowel fistula), a chronic abuse of laxative, malabsorption syndromes,
mucus secreting villous adenoma of
the small intestine, or renal salt-losing conditions (renal disorders,
overuse of diuretics), particularly in
cases (e.g. starvation) where a source of energy is required.
4.2 Posology and method of administration
Posology
_Adults, the Elderly and Children_
The dosage depends on the age, weight, clinical and biological
conditions of the patient and concomitant
therapy.
Typical doses of potassium for the prevention of hypokalemia may be up
to 50 mmoles daily and similar
doses may be adequate in mild potassium deficiency. In severe acute
hypokalemia, up to 20 mmoles of
potassium in 500 ml over 2 to 3 hours under ECG control. Patients with
renal impairment should receive
lower doses.
The maximum recommended dose of potassium is 2 to 3 mmol/kg/24h. The
rate should not exceed 10 to
40 mmol/h to avoid hyperkalaemia. For peripheral infusions, potassium
concentration should be less than
60 mmol/l to avoid pain.
The maximum rate of glucose is about 500 to 800 mg/kg/h.
_Paediatric Population _
The infusion rate and volume depends on the age, weight, clinical and
m